252 Chapter 11 Table 3. Continued Reference Level of Testing Name Genes, Molecules or Panel Investigated Type of Analysis Performed Gene or Molecule Name and Mutation or Expression Status (n) No. of Patients with PM (N) and Outcomes (n) No. of Patients without PM (N) and Outcomes (n) MMR Status (MSI/MSS) Findings as Reported by Authors in Studies Nagahara et al. 31 RNA Kif18A RT-PCR N = 6 N = 107 N/A Kif18A overexpression in CRC significantly correlated with PM (p = 0.02 d). Kif18A low expression 0 38 Kif18A high expression 6 69 Prasanna et al. 45 - BRAF, RAS - N = unknown N = unknown PM: 29/239 M0: 77/940 BRAF-mutated colorectal cancer showed higher incidence of PM with a relative risk of 1.8 (p < 0.001 e). KRAS-mutated patients showed no higher incidence of PM with a relative risk of 0.95 (p = 0.63 e). RAS mutant (965) 199 766 RAS wild-type (1271) 274 997 BRAF mutant (143) 51 92 BRAF wild-type (1058) 208 850 Roberto et al. 46 - BRAF - N = 53 N = 154 Total: 19/66 BRAF mutant right colorectal cancer was significantly more likely to occur with peritoneal metastases (38.1% vs. 22.4%, p = 0.003 d). BRAF mutant (42) 16 26 Sakuraba et al. 32 RNA Tip60 RT-PCR N = 5 N = 33 N/A The authors found that Tip60 downregulation (compared to healthy tissue expression) showed significant correlation with PM (p = 0.0053 d). Downregulation of Tip60 expression 3 2
RkJQdWJsaXNoZXIy MTk4NDMw